Combination with anti–CTLA-4 led to tumor regression accompanied by enhanced T cell activity, increase in activated CD86+ monocytes in the tumor, augmentation of pro-inflammatory IFNγ, TNFα, and IL-6 and decrease in immunosuppressive MCP-1 and IL-10 cytokines (195). The gene discussed is CTLA4; the disease is neoplasm.